Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring

Chase W Kessinger, Jin Won Kim, Peter K Henke, Brian Thompson, Jason R McCarthy, Tetsuya Hara, Martin Sillesen, Ronan J P Margey, Peter Libby, Ralph Weissleder, Charles P Lin, Farouc A Jaffer

49 Citationer (Scopus)

Abstract

Despite anticoagulation therapy, up to one-half of patients with deep vein thrombosis (DVT) will develop the post-thrombotic syndrome (PTS). Improving the long-term outcome of DVT patients at risk for PTS will therefore require new approaches. Here we investigate the effects of statins-lipid-lowering agents with anti-thrombotic and anti-inflammatory properties-in decreasing thrombus burden and decreasing vein wall injury, mediators of PTS, in established murine stasis and non-stasis chemical-induced venous thrombosis (N = 282 mice). Treatment of mice with daily atorvastatin or rosuvastatin significantly reduced stasis venous thrombus burden by 25% without affecting lipid levels, blood coagulation parameters, or blood cell counts. Statin-driven reductions in VT burden (thrombus mass for stasis thrombi, intravital microscopy thrombus area for non-stasis thrombi) compared similarly to the therapeutic anticoagulant effects of low molecular weight heparin. Blood from statin-treated mice showed significant reductions in platelet aggregation and clot stability. Statins additionally reduced thrombus plasminogen activator inhibitor-1 (PAI-1), tissue factor, neutrophils, myeloperoxidase, neutrophil extracellular traps (NETs), and macrophages, and these effects were most notable in the earlier timepoints after DVT formation. In addition, statins reduced DVT-induced vein wall scarring by 50% durably up to day 21 in stasis VT, as shown by polarized light microscopy of picrosirius red-stained vein wall collagen. The overall results demonstrate that statins improve VT resolution via profibrinolytic, anticoagulant, antiplatelet, and anti-vein wall scarring effects. Statins may therefore offer a new pharmacotherapeutic approach to improve DVT resolution and to reduce the post-thrombotic syndrome, particularly in subjects who are ineligible for anticoagulation therapy.

OriginalsprogEngelsk
TidsskriftP L o S One
Vol/bind10
Udgave nummer2
Sider (fra-til)e0116621
ISSN1932-6203
DOI
StatusUdgivet - 2015
Udgivet eksterntJa

Fingeraftryk

Dyk ned i forskningsemnerne om 'Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring'. Sammen danner de et unikt fingeraftryk.

Citationsformater